In 118 adults with advanced soft tissue sarcoma, adding regional hyperthermia to trabectedin did not improve PFS (median 3.0 vs 3.5 months; HR 0.86, P=0.459); three treatment-related deaths occurred with trabectedin alone.
RCTn = 118
Schuebbe et al. A randomized clinical study comparing trabectedin combined with regional hyperthermia with trabectedin in patients with advanced soft tissue sarcoma: HyperTET, a German Interdisciplinary Sarcoma Group trial